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Abstract
Zika virus (ZIKV) is a mosquito-transmitted flavivirus that is causing significant worldwide health concern. There are currently no treatments or vaccines available for this virus, thus,
there is an urgent need to develop a safe and effective vaccine to combat ZIKV infection.
Nhumirim virus (NHUV) is also a mosquito-transmitted flavivirus, but it is unable to infect
humans and other vertebrate animals, making it an ideal candidate to develop chimeric viral
vaccines against other disease-causing flaviviruses, such as ZIKV. In this study, we generated
chimeric viruses by replacing envelope (E) gene in the genome of NHUV with ZIKV E gene,
which encodes the major viral surface glycoproteins that mediate cellular receptor binding and
induce host protective immune responses. The recombinant NHUV genomes were transfected
into mosquito C6/36 cells in the forms of plasmids. The transfected cell supernatants were then
collected and used to inoculate a new batch of C6/36 cells on day 4 post-transfection. The cell
supernatants were continuously passed for five passages on C6/36 cells. Although a cytopathic
effect (CPE) was not observed on the days of collection, the presence of the chimeric viral
genomes of the chimeric viruses was confirmed by using RT-qPCR measuring ZIKV E and
nonstructural gene 1 (NS1) of NHUV. The results of this study indicate the successful generation
of chimeric ZNHUV viruses that can be further evaluated in cell culture and in a mouse model as
a potentially safe and effective vaccine candidate against ZIKV infection.
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Chapter 1: Introduction
Zika Virus (ZIKV) belongs to the family Flaviviridae and has posed threats to the
health of individuals, especially those in the Americas (9). Outbreaks of the other viruses
that belong to the same family as ZIKV have also caused severe loss of lives and created
a health and financial burden in other regions (9).
Insect-Specific Flaviviruses (ISFs) are a group of viruses from the Flaviviridae
family that cannot infect humans and other mammals (9). These viruses replicate in
mosquitoes; however, they will not infect vertebrates like humans (17). Cell Fusing
Agent Virus (CFAV) was the first ISF to be discovered, and it has been used as a model
to understand other ISFs, such as Long Pine Key Virus (LPKV) and Nhumirim Virus
(NHUV) (9). As technological advances have increased over the years, additional ISFs
are being discovered. These ISFs have been looked at as a means of combatting the
flaviviruses damaging human populations.
In this project, a recombinant virus, in the form of a plasmid, was used to infect
C6/36 mosquito cells that were derived from the mosquito species, Aedes albopictus. The
envelope E gene of NHUV was replaced with that of ZIKV. We also examined the
effects of the NHUV and inferred how this methodology could be applied to future
studies in vaccine creation.
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Chapter 2: Literature Review
Arboviruses are a group of viruses that use arthropods like mosquitoes as their
vectors (23). In fact, research has shown that mosquitoes cause over ninety percent of
arboviral related diseases in humans (9). Both positive-sensed and negative-sensed RNA
viruses are found in this group, such as Flaviviridae and Bunyaviridae. The name
“Flaviviridae” is obtained from the Latin word “flavus”, which means “yellow” (4).
Yellow fever virus is one of the most well-known viruses in this family. Virus genera in
this family include Flavivirus, Pestivirus and Hepacivirus (4). There are more than 70
viruses in the genus of Flavivirus, and most of them are important human pathogens.
In the Flavivirus genus, the viruses are classified based on host/vector (9). The
first group consists of insect-specific flaviviruses (ISF), which indicates that these viruses
only infect insects. Since they are unlikely to grow in vertebrates, they use the process of
vertical transmission to maintain their existence (17). Examples of ISFs include CFAV,
LPKV, and NHUV (9). The other group of the Flavivirus genus consists of viruses that
can infect both invertebrate insects and vertebrates. They are called dual-host MosquitoBorne Flaviviruses (MBFVs) (17). Examples of MBFVs include Dengue Virus (DENV),
Zika Virus (ZIKV), West Nile Virus (WNV) and Japanese Encephalitis Virus (JEV).
Sometimes, flaviviruses are classified into a third cluster that has no known vector
(NKV) (17). Apart from the host classification, flaviviruses can also be classified based
on their epidemiology (9). Flaviviruses can cause a range of human diseases, such as
Dengue Fever and Yellow Fever (9). The diseases and infections they cause range from
neurologic diseases, to hemorrhagic diseases, to even mild febrile diseases (9). For
example, ZIKV causes microcephaly in the unborn children of infected mothers and JEV
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causes brain diseases. Geographic distribution, antigenicity, and nucleotide sequences are
other means of classifying flaviviruses (10). Also, flaviviruses are diverse in terms of
distribution, vectors, and hosts, which makes it more complex for them to be classified
(19). In addition, we do not fully understand the broader ecological cycle of flaviviruses
(4). Due to the advancement of molecular techniques, more flaviviruses are being
discovered worldwide (20), thus the true number of flaviviruses that exist today is
presently unknown.

Figure 1: Geographical distribution of flaviviral host cell richness
https://www.ucdavis.edu/news/where-will-worlds-next-zika-west-nile-or-dengue-viruscome/
Over 50% of the viruses in the flavivirus group are human pathogens that cause
deadly diseases (4), and there is an urgent need to address and mitigate their threat to the
human population. According to the World Health Organization, there are over 50
million new cases of Dengue fever per year. Likewise, deaths in Asia due to JEV and the
Tick-Borne Encephalitis Virus in central Europe represent additional threats to people
within these regions (4). The global distribution of the West Nile Virus (WNV) is also a

3

major threat, as it affects the human populations of Africa, Southern Europe, and North
and South America (4). The lack of vaccines, drugs and methods of appropriate vector
control is leading to the continued reemergence of these viruses (21).
As the years have gone by, additional flaviviruses have emerged and reemerged
and their incidence level has increased (4). In 1952, Zika Virus (ZIKV) infection was first
reported in humans (17). Before then, the virus had only been isolated in a Ugandan
rhesus monkey in the Zika forest in 1947 (10, 7). Although ZIKV was initially isolated
from the Aedes africanus mosquito, it was unclear whether it could infect humans until
the first ZIKV related human illness was recognized in a Nigerian citizen (16). ZIKV is
primarily transmitted via mosquitoes but it also can be passed on by other routes, such as
sexual contact, mother-to-fetus transmission, and blood transfusions (Figure 2). ZIKV
has been isolated from several species of mosquitoes including Ae. africanus, Ae. aegypti,
Ae. hensilli, Ae. furcifer, and Ae. apicoargenteus (11). Similar to other flavivirus group
members, ZIKV is also an RNA virus. It has a striking similarity to the Spondweni virus,
having 10,794 nucleotides and 3,419 amino acids that it encodes (11). In terms of
underlying pathogenesis, ZIKV is thought to replicate in dendritic cells, lymph nodes,
and bloodstream, just like other mosquito-borne flaviviruses (11). Similar to many other
flavivirus types, the incubation period of ZIKV is estimated to be less than one week
(16). However, ZIKV replication during infection is different from other flaviviral types,
as its antigens can be found in cell nuclei, rather than simply in the infected cell
cytoplasm (11).
Zika Virus’s African strain causes less severe illnesses compared to the Asian
lineage strain, which is responsible for many severe symptoms, such as congenital
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syndrome (17). Studies conducted in 1968 showed that 40% of the humans in Nigeria
from whom ZIKV was isolated had neutralizing antibodies to the virus (11). In 2007,
there was an outbreak of ZIKV that caused diseases with mild symptoms, such as
conjunctivitis and arthralgia in a region of the Pacific Ocean called the Yap Islands (12),
and more severe illnesses such as the Guillain-Barre syndrome were recorded (16). It was
noted that the Aedes hensilli was the ZIKV vector responsible in the Yap Islands (16).
This outbreak marked the first documentation of ZIKV detection outside of Africa and
Asia (9, 13, 8), which was surprising as there were about 5000 infections documented
(15, 8) from this outbreak. From the Yap Islands, several other outbreaks started to occur
on other islands in the Pacific Ocean, such as the Easter and Cook Islands (15, 22, 18).
Although there were significant cases documented before 2007, the Zika epidemic turned
into a Zika pandemic between 2015 and 2016 (17).
Recently, ZIKV reemerged in some tropical regions, such as Brazil (17), and it
has been noted that it was introduced from the Pacific Islands (16). The reemergence of
ZIKV caused a global alarm because its infection could be linked to human birth defects,
and this was only one of the major infectious diseases capable of causing such defect in
more than half a century (16). Microcephaly, which is a condition associated with
abnormal brain development and small head size (16), is one of the effects when ZIKV is
passed from pregnant mothers to their fetus. The Brazilian Ministry of Health, the
Centers for Disease Control and Prevention (CDC), and the World Health Organization
issued an alert on the ZIKV-associated congenital malformation during the outbreak (17).
The presence of ZIKV RNA has been confirmed both in the amniotic fluid and brain
tissue of fetuses that developed microcephaly, hence there is a strong link between the
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microcephaly deformity and Zika infection (16). Between September 2015 and February
2016, the cases of ZIKV-associated microcephaly in Brazil reportedly reached 4,300
(16). There have also been reported cases of peripartum related transmissions of ZIKV
(16). In these cases, the symptoms range from some individuals being asymptomatic to
others having rashes and illnesses (16). Sexual transmission has also been documented as
a means of this viral spread (Figure 2). ZIKV viral particles have also been found in
breast milk; however, transmission via breast milk has yet to be confirmed (16). It has
been estimated that close to half of the world’s population is at risk of becoming infected
(9), therefore there is an urgent need to develop vaccines and antivirals.

Figure 2: Transmission of Zika Virus (ZIKV) https://www.cdc.gov/zika/pdfs/ZikaTransmission-Infographic.pdf
As Insect-Specific Flaviviruses (ISFs), are unable to infect humans, they have
been looked as a possible means by which vaccine development can be achieved. CFAV
is the first flavivirus that was isolated from a line of Aedes aegypti cells (6). Thirty-eight
ISFs have been documented as of November 2016, including NHUV and CFA, and many
others are currently being discovered due to the advancement of molecular techniques
(6).
6

NHUV was discovered in 2010 in Culex chidesteri mosquitoes (9) from the
Brazilian Pantanal region (17). Previous studies suggest that NHUV may have lost its
ability to replicate in vertebrate cells (9). In addition, some studies have shown that
NHUV suppresses the growth of WNV (17). Furthermore, research has also shown that
when NHUV is superinfected or co-inoculated with ZIKV, the growth of ZIKV is
suppressed (17). NHUV can infect and replicate in C6/36 cells that were derived from
Aedes albopictus, causing a cytopathic effect (CPE) (21). Plaque assays in C6/36 cells
can be employed to determine NHUV titers in a viral stock (21). Likewise, C6/36 is
suitable for studying other ISFs, and Vero cells derived from African green monkey
kidneys are also a potential cell line used to study human and vertebrate viruses. Vero
cells have been shown to lack the type I interferon response, making them susceptible to
infection by many mammalian viruses (5).
Prior research has shown that when grown in cell culture, pathogenic flaviviruses
may cause cytopathic effects; thus, if a vaccine is made to protect against a flavivirus, it
needs to be safe (4). Other requirements for a good vaccine include thermal stability, ease
of production, and low production cost (4). For some vaccines, prophylactic relevance
will also be needed in order to combat more than one virus serotype (4). Thus, the
development of a vaccine for DENV is particularly difficult because of its existence in
multiple serotypes (4).
The genome of a flavivirus is approximately 11 kb in length, with an open reading
frame that encodes three structural proteins and seven nonstructural proteins (Figure 3).
Collectively, the various proteins of flaviviruses have individual roles in the viral
replication process (3). When a flavivirus successfully infects a host, it translates its
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genome into a polyprotein within the cytoplasm and is then subsequently cleaved by
proteases to yield three structural proteins and seven nonstructural proteins (15). The C,
prM, and E are the three structural proteins and NS1, NS2A, NS2B, NS3, NS4A, NS4B,
and NS5 are the seven nonstructural proteins (9). The NS1 gene was first reported as a
viral antigen in Dengue patients in 1970 (14) and it is relatively conserved among all
flaviviruses (14). NS1 is described as enigmatic since it has several oligomeric forms and
also serves as a biomarker for detecting diseases early (14). NS1 is not restricted to one
location in the cell (14). When it is intracellular, it plays a significant role in the viral
replication process, but its specific function is currently unknown (14). In some studies,
the NS1 glycosylation sites have been eliminated to create a hypothetic vaccine for some
flaviviruses (1). The E protein has significant functions in helping the virus with host cell
entry and assembly (15). For example, ZIKV in its mature form has been shown to
contain 90 antiparallel E dimers when viewed in high resolution (15).

Figure 3: Flaviviral genome (2). A shows the single-stranded positive-sense RNA of a
flavivirus with its seven nonstructural genes in red and three structural genes in blue. B
shows the predicted transmembrane domains for the structural and nonstructural proteins.
Currently, the World Health Organization has reported approximately 38 ZIKV
vaccine candidates and few of those have progressed to the clinical phase trial (12). It is
8

expected that a vaccine developed for ZIKV should have the capacity to not only prevent
infection but to also protect the host against the pathological conditions that come with
the viral infection (12). The types of vaccines developed include DNA and mRNA
vaccines, attenuated vaccines, and viral-like particles or proteins (12). Each of these
forms has its own advantages. For example, the live attenuated form has shown
significant success in protecting against flaviviruses such as JEV, therefore it is expected
that similar success will be observed with a ZIKV vaccine (12). In addition, the live
attenuated forms are cost-effective and can induce the humoral and cellular immune
responses within their hosts (12). The virus-like particles can induce antibody responses
and are much stronger while the DNA vaccines are relatively easier to engineer and
manufacture.
In this study, we utilized the NHUV genome as a backbone to replace the NHUV
E gene with the ZIKV E gene to create a chimeric virus named ZNHUV. A plasmid was
used in transfecting this ZNHUV into the mosquito cells. The envelopes of flaviviruses
originate from the host cell lipid membrane during viral replication (3). The E gene
specifically encodes for envelope proteins, which are glycoproteins that are inserted into
the viral envelopes. These E proteins mediate cellular receptor binding and induce host
protective immune responses. In this project, we transfected the plasmids of the chimeric
ZNHUV genome into C6/36 mosquito cells and monitored the cytopathic effect.
Subsequently, we used the RT-qPCR method to measure the presence of the ZIKV E
gene and the nonstructural gene 1 (NS1) of NHUV in the cDNA. The results of this study
will be used to determine if this chimeric virus methodology can be successfully used for
ZIKV vaccine development.
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Chapter 3: Methods and Materials
3.1. Experimental Outline Overview. The purpose of this study was to generate chimeric
viruses by replacing the envelope E gene in the NHUV genome with the ZIKV E gene.
After transfection, the peak day of infection for NHUV was first determined by RT-qPCR
and plaque assay. The time with the highest viral genome concentrations was then used to
collect the recombinant viruses. The transfected cells and supernatants were collected and
used to inoculate a new batch of C6/36 cells for five generations. Following the
collection of the cells from each passage, RT-qPCR was used to measure the presence of
both the ZIKV E and the nonstructural gene 1 (NS1) of NHUV.

3.2. Cell Subculture. C6/36 cells were obtained from ATCC (CRL-1660™) and cultured
in the growth medium, EMEM, with 10% FBS and 1% P/S in an incubator at 28°C with
5% CO₂. For subculture, the EMEM medium from the growth flask was discarded and
the cells were washed with PBS. The PBS used for washing was again discarded and
another 9 ml was added together with 1 ml of Trypsin-EDTA. The flask was then placed
in the incubator for 5 minutes until the cells had successfully visibly detached from the
flask’s surface. Next, 10 ml of EMEM with 10% FBS and 1% P/S was added, and the
mixture was transferred into a 50 ml centrifuge tube. The mixture was centrifuged for 5
minutes at 1500 rpm and after centrifugation, the supernatant was discarded through
decantation. The resulting cell pellet was diluted with 10 ml of EMEM and then a
subsample was re-added into the flask for further incubation. The remaining sample was
counted and used for plating purposes.
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3.3. C6/36 Viral Infection with NHUV. Healthy C6/36 cells were plated in 6-well plates
following 3 days of growth. Approximately 1 × 106 cells were added per well and
incubated overnight to achieve a monolayer of 100% confluency. The growth medium
was removed from the confluent C6/36 cells after one day and replaced with 1ml of the
viral growth medium. The cells were incubated with NHUV for an additional hour at
28°C. After incubation, 1 ml of fresh cell growth medium was added, and the cells were
allowed to continue incubation. Between days 4 and 5 when cytopathic effects were
observed, the supernatant was collected and used to further infect the next batch of cells.

3.4. Plaque Assay of NHUV. Plaque assay was used to calculate the plaque-forming units
of NHUV, essentially the viral titer. To do this, the above viral infection process was
followed. After one hour of the incubation, the supernatant was removed and a mixture of
plaque agarose and EMEM medium was applied on the cells. After solidification at room
temperature, the plates were incubated for 3~4 days. Once plaques started to form, the
cells were stained with neutral red. The plaques were counted under bright light and the
plaque-forming units (pfus) were calculated.

3.5. Transfection of C6/36 cells with ZNHUV. Healthy C6/36 cells were plated at an
amount of 1 × 106 per well in a 6-well plate and incubated in a 28°C incubator with 5%
CO₂ overnight. The following day, 5 μl of Flyfectin reagent (OZ Biosciences) was mixed
with 125 μl of Opti-MEM medium in a sterile Eppendorf tube by pipetting up and down
several of times. In another Eppendorf tube, 2 μl of plasmid DNA of ZNHUV was diluted
in 125 μl of Opti-MEM medium. Two μl were added and mixed well again by pipetting
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up and down. After, the diluted DNA was added into the tube containing diluted Flyfectin
and the solutions were mixed well one more time. This mixture was incubated for 15
minutes at room temperature in a biosafety hood.
The incubated C6/36 cells from the previous day were gently washed with
antibiotic-free EMEM-FBS medium, then 1ml of the EMEM medium was added per well
and left to sit. After the 15-minute incubation period, the mixture of Flyfectin and
ZNHUV plasmid was added to the individual wells containing C6/36 cells and incubated
at 37°C for 8 hours. After incubation, the antibiotics free media in each well was
removed and replaced with 2ml of growth medium. The cells were then kept in a 28°C
incubator for 7 days after which, the supernatant, which contained viral particles, was
collected to be used for secondary infection assays.

3.6. Supernatant Collection and RNA Isolation. After proper labeling of the tubes, the
medium supernatant from each well was collected into individual Eppendorf tubes and
centrifuged at 1500 rpm for 10 minutes at 4°C. Next, the supernatant was carefully
transferred into a clean sterile Eppendorf tube. To extract total RNA from the cells, an
RNeasy extraction kit (Qiagen) was used following the manufacturer protocols. The total
RNA was then reverse transcribed into first strand cDNA using the iScript cDNA
synthesis kit (BioRad).

3.7. Quantitative RT-qPCR. A real-time qPCR amplification was performed to amplify
both the NHUV NS1 and the ZIKV E genes. A probe-based qPCR was carried out for the
ZIKV E gene investigation, while a SYBR green-based PCR was carried out for the
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NHUV NS1 gene. The standard curves were acquired using serial dilutions of a standard
with known concentration. Mosquito housekeeping gene Rp7 was used as an internal
control for NHUV. For the qPCR conditions, the first step involved the samples running
at 95°C for 5 minutes, then for 25 seconds at 95°C and 60°C for 1 minute in the second
step, and for the final step, the second step was repeated for 40 cycles. The qPCR primers
and probes were synthesized by Integrated DNA Technologies (IDT). All the qPCR
reagents were purchased from Bio-Rad.

3.8. Statistical Analysis. The data collected were analyzed using analysis of variance
(ANOVA) in GraphPad Prism 6 software. The ANOVA analysis was followed by
Tukey’s test.
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Chapter 4: Results
4.1. NHUV Causes Significant CPE in C6/36 cells
C6/36 mosquito cells were subcultured with the EMEM cell growth medium.
After plating in six-well plates, the cells were left to grow overnight in EMEM, 10% FBS
and 1% Penicillin-Streptomycin until a monolayer formed with almost 100% confluency.
The cells were then infected with NHUV and incubated for a week. The uninfected plate
that was used as a control showed continuous growth of small, rounded C6/36 cells
(Figure 4), while those infected with NHUV showed a significant cytopathic effect (CPE)
(Figure 4) as the cells clumped and fused together. As shown in Figure 5, the higher the
viral concentration, the greater the CPE seen (Table 1). Plaque assays were performed,
and they showed that the titer of the NHUV stock was 6.5 × 106 pfu/ml using the
formula:
pfu =

𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑙𝑎𝑞𝑢𝑒𝑠 𝑓𝑜𝑟𝑚𝑒𝑑
4

× 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟

Figure 4: Comparison of CPE for
different concentrations of NHUV
infected and uninfected C6/36 cells.
The uninfected C6/36 cells are round
and almost confluent. The various
concentrations of NHUV infected
C6/36 cells show cell fusing and
clumping, essentially CPE.
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Control

NHUV 10−7 dilution NHUV 10−8 dilution

Figure 5: Plaque assay of various concentrations of NHUV infected C6/36 cells.
Plaques are well rounded and seen by day 4 of NHUV infection.
Dilution Factor
1

10

106
107
108

Number of plaques
Too many to be counted
46
31
9

Table 1: The number of plaques per well and the corresponding dilution factor is shown.

4.2. Peak Viral Infection of NHUV
The RT-qPCR results showed that NS1 copy numbers reached the peak on day 4
post-infection (Figure 6). This was relatively consistent with the plaque assay results,
indicating that the viral titer peaked on day 5 in the supernatants (Figure 7).
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Figure 6: RT-qPCR measuring NHUV RNA replication. The copy numbers of NHUV
NS1 gene were quantified by the RT-qPCR and Rp7 was used as the housekeeping gene
internal control. This graph shows that NHUV viral replication was highest on day 4
post-infection. The data represent the results of two independent experiments and were
analyzed by one-way ANOVA followed by Tukey’s test (* and ** denote p < 0.05 and p
< 0.01 respectively, when compared to day 1 post-infection).
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Figure 7: Plaque assay measuring infectious viral particles in the cell medium. A
plaque assay was performed using the supernatant collected each day post-infection. This
graph shows that the highest number of plaques was observed on days 4 and 5 postinfection. The data represent the results of two independent experiments, and were
analyzed by one-way ANOVA, followed by Tukey’s test (** denotes p < 0.01, when
compared to day 1 post-infection).

4.3. Verification of the Formation of ZNHUV via RT-qPCR
ZNHUV plasmids were transfected into C6/36 cells, and the cells were inspected
daily for one week. No CPE was observed in neither the negative control nor the ZNHUV
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transfected group. The RT-qPCR was conducted to quantify ZIKV E gene using probebased qPCR, while the NHUV NS1 was quantified by using SYBR green-based qPCR.
The qPCR results indicated that there was a similar trend between the ZIKV E and
NHUV NS1 gene expression. The first infection showed the highest amplification for
both genes (Figure 8), which may be due to the high numbers of plasmids that were
transfected into the cells initially. There was a reduction in the second and third
generations compared to the first generation, but amplification started to show a trend of
increase in the fourth and fifth generations. The reason could be that the new chimeric
viruses need to take several generations to adapt to the cell culture before producing
higher viral titers. Due to the presence of both ZIKV E and NHUV NS1 even after the
fifth generations, our results indicate the successful production of ZNHUV, a chimeric
virus that can be potentially evaluated as a ZIKV vaccine candidate.

300

NHUV NS1 copy number

0

1

2

3

4

100

0

5

1

Generation

5

500

4

1000

200

3

1500

2

ZIKVE (Starting quantity)

NHUV 4
2000

Generation

Figure 8. RT-qPCR results measuring ZIKV E gene and NHUV-NS1 gene. The
graph shows copy numbers of ZIKV E and NHUV NS1 in the 5 generations. For the first
generation, there was a higher rate of infectivity of both ZIKV and NHUV. This trend
continued to decline until generation 4, where the levels of both target virus genes started
to increase again. Statistical analysis was not performed because only one experiment
was conducted (no repeats).
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Chapter 5: Discussion
The emergence and re-emergence of human pathogenic flaviviruses is a global
health concern (9) and currently, specific vaccines are not available for most of the
flaviviruses. As a consequence, the development of safe and effective vaccines against
pathogenic flaviviruses remains a top priority. A central problem with finding a vaccine
for ZIKV, in particular, is that about 80% of the cases in patients are asymptomatic which
impedes the process by which follow-up volunteers can report (12). Zika continues to be
a global problem in several regions and there is a critical need for a vaccine. The primary
goal of this study was to test the hypothesis of whether NHUV can be used as a backbone
to generate ZIKV vaccine candidates. The Envelope (E) gene from ZIKV was used to
replace the Envelope (E) of NHUV. The target plasmid product which contained the
ZNHUV recombinant virus was transfected into C6/36 cells. These cells were grown for
a week and the supernatant was used to re-infect five more generations consecutively. In
addition to this, total RNAs from the infected cells were extracted during all five
generations.
To grow the original wild-type NHUV stock, C6/36 cell lines were infected to
collect the cell medium supernatant. We found that NHUV replicated with the highest
concentration on day 4 post-infection (Figure 6). Thus, the ZNHUV supernatants and
cells were collected on that day throughout all the five generations. The original wildtype NHUV can cause severe cytopathic effects (CPE) starting from day 2 post-infection
(Figure 5). The CPE includes cell lysis and fusion. The more concentrated the viruses are,
the earlier the CPE appears. Previous studies have shown that flaviviral infections can
lead to both apoptosis and necrosis with an extreme level of viral load in vivo (19). These
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viruses have the ability to activate the tumor necrosis factor α (TNF α) and other
pathways leading to apoptosis (19). When ZNHUV was used to infect the C6/36 cells,
there was no visible CPE. Based on physical visibility, we could not tell the difference
between the ZNHUV infected C6/36 cells and the uninfected C6/36 control cells. When
plaque assays were performed for ZNHUV infected cells, there was also no obvious
plaque formation. These results indicate that ZNHUV either has a low concentration or
has less infectivity compared to the wild type NHUV, which may be because the new
chimeric ZNHUV needs to adapt to the cells by acquiring natural mutations after serial
passages in the cell culture. Despite the fact that CPE was not observed in the infection
with ZNHUV, the presence of the chimeric virus was confirmed using RT-qPCR to
measure the presence of both ZIKV E and NS1 gene of NHUV (Figure 8). The expression
levels of ZIKV E and NS1 were similar, with the first generation showing the maximum
level of viral infection, which may be due to the high numbers of plasmids that were
transfected into the C6/36 cells initially. After a brief reduction in the second and third
generations, ZNHUV gradually might adapt to the cell culture and produce higher viral
titers in the fifth generation. In summary, these results show the successful generation of
a chimeric virus (ZNHUV) that carries ZIKV E in the NHUV genome backbone.
Previous studies have reported the wide-spread use of C6/36 cells in many studies
in vitro, although it is limited due to its defectiveness in antiviral immunity (9).
Furthermore, other studies have shown that results from in vitro studies never completely
match results from in vivo studies (5). Compounding this, NHUV is a relatively new virus
that has not yet been fully explored regarding its infectivity in mosquitoes. This study is a
preliminary exploration using NHUV to generate vaccine candidates against another
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important human pathogen flavivirus, ZIKV. The next step is to test if ZNHUV can infect
Vero cells and evaluate if it can generate immunity against ZIKV infection in a mouse
model.
ZIKV is hypothesized to have originated from Africa, then spread to Asia and the
Americas (16). Those strains in the Americas have the Asian genotype, being distinct
from the African strain (16). Due to this, it is essential that any vaccine developed to
combat the virus has to be effective for all strains (16). In the meantime, since there are
no ZIKV vaccines that have been approved, preventative measures must be taken to
prevent its spread (16). For example, the mosquito vectors can be controlled by
eliminating breeding sites or using insecticides and larvicides, or the rate of sexual
transmission can be reduced (16). The vector control mechanism has its limitations
depending on the scale. When viewed on a large-scale, vector control mechanism does
not show as much promise compared to smaller-scale measures (14). In addition, it will
be difficult for less developed countries to achieve effective vector control mechanisms
(14). Flaviviral mutations have added to the spread of the viruses in new populations
(16). This together with increased globalization and urbanization are likely reasons for
the continuous emergence and reemergence of ZIKV and other flaviviruses (16). This is
because the aforementioned processes involve an increase in temperatures, human
movement, an increase in goods transportation, and also population densities (14).
In conclusion, the results presented in this thesis provide some preliminary but
essential methodological understanding of the infectivity of NHUV. The results also
indicate that a chimeric ZNHUV virus can be successfully developed. Ultimately, this
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study lays a foundation for the further development of safe and effective vaccines for
ZIKV, using the NHUV genome as a backbone.
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